Although statins are currently the main treatment for hypercholesterolemia, many patients are statin intolerant [3–5] and inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has recently emerged as an alternative or parallel approach to reduce cholesterol levels [6–9]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.